anti-Nipah_240
| anti-Nipah_ID | anti-Nipah_240 |
| anti-Nipah Drug | Favipiravir |
| Nipah virus strain | NiV (Malaysia ) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | In-vitro |
| Models used to test anti-Nipah activity | Vero CCL81 |
| Mode of infection to test anti-Nipah activity | Adsorption |
| Viral titer to test anti-Nipah activity | 0.01 MOI |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | Post Infection |
| Duration of Drug delivery for anti-Nipah activity | 48 hours |
| Drug concentration used to test anti-Nipah activity | 44.24 μM |
| Assays used to test anti-Nipah activity | Plaque assay |
| anti-Nipah activity | Decrease [Effective concentration (50 %)] |
| Cytotoxicity of anti-Nipah compounds | >1000 μM |
| References | Dawes BE, Kalveram B, Ikegami T, Juelich T, Smith JK, Zhang L, Park A, Lee B, Komeno T, Furuta Y, Freiberg AN Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci Rep. 2018 May 15;8(1):7604. doi: 10.1038/s41598-018-25780-3. |
| Comments | Favipiravir has potent antiviral activity against henipaviruses. In vitro, favipiravir inhibited Nipah and Hendra virus replication and transcription at micromolar concentrations. In the Syrian hamster model, either twice daily oral or once daily subcutaneous administration of favipiravir for 14 days fully protected animals challenged with a lethal dose of Nipah virus. |